Baxter International (BAX) is one of the leading medical technology companies in the United States. It offers renal and hospital products to healthcare providers. For a brief introduction to the company, read Getting to Know the New Baxter: Key Growth Drivers for 2016.
Let’s take a look at Baxter by analyzing Wall Street analyst recommendations and target prices for the company over the next 12 months. In a Reuters survey of 16 brokerage companies on December 23, 2016, about 25.0% of the analysts rated Baxter International a “buy,” and 68.8% rated it a “hold.” About 6.2% of them rated it a “sell.”
Receive e-mail alerts for new research on BAX:
Interested in BAX?
Don’t miss the next report.
The above table provides a recommendation summary for Baxter International over the next year. The consensus 12-month target price for the company is $53.25, a ~20.5% return potential. Baxter was trading at $44.20 on December 22, 2016.
According to analysts’ most recent recommendations, the lowest one-year target price for Baxter International was $47, implying a ~6.3% return potential over the next 12 months. Baxter’s highest one-year target price was $60, implying a ~35.7% return potential over the next 12 months.
ResMed (RMD), Becton Dickinson & Co. (BDX), and C.R. Bard (BCR) have average broker target prices of $181, $242.90, and $62.30, respectively. These figures imply returns of 4.8%, 12.5%, and 0.30%, respectively, over the next 12 months.
If you’re interested in gaining focused exposure to Baxter International, you could consider investing in the iShares US Medical Devices (IHI). IHI has 3.7% of its total holdings in Baxter International and is one of the largest US medical device ETFs. It tracks the Dow Jones U.S. Select Medical Equipment Index.
You could also consider investing in healthcare sector ETFs such as the Health Care Select Sector SPDR ETF (XLV) for exposure to Baxter International. XLV has ~0.81% of its total holdings in Baxter. For more industry-diversified exposure, you could also invest in the iShares Core S&P 500 (IVV), which has ~0.11% of its total holdings in Baxter.